Cognition Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CGTX Nasdaq 2836 www.cogrx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cognition Therapeutics, Inc.

Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis - May 21st, 2026 5:30 am
Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies - May 14th, 2026 5:30 am
Hantavirus Outbreak Shows Need for Broad-Spectrum Antiviral Drugs - May 12th, 2026 6:35 am
Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update - May 7th, 2026 2:15 pm
NanoViricides to Participate at D. Boral Capital Global Conference in NYC - May 7th, 2026 6:35 am
NanoViricides’ Measles Treatment Granted Orphan Drug Designation by FDA - May 6th, 2026 6:35 am
Cognition Therapeutics Targets Faster DLB Psychosis Path as Zervimesine Nears Late-Stage Plans - Apr 13th, 2026 2:35 pm
Cognition Therapeutics to Present at Needham Virtual Healthcare Conference - Apr 7th, 2026 5:30 am
Cognition Therapeutics CEO Issues Letter to Shareholders - Mar 31st, 2026 2:30 pm
Cognition Therapeutics Inc (CGTX) Q4 2025 Earnings Call Highlights: Promising Developments in ... - Mar 26th, 2026 1:02 pm
Cognition Therapeutics Q4 Earnings Call Highlights - Mar 26th, 2026 8:07 am
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update - Mar 26th, 2026 5:30 am
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results - Mar 23rd, 2026 5:30 am
Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026 - Mar 17th, 2026 5:30 am
Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis - Mar 2nd, 2026 5:30 am
Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies - Feb 5th, 2026 5:30 am
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies - Jan 27th, 2026 5:30 am
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies - Jan 6th, 2026 5:30 am
Will Cognition Therapeutics (NASDAQ:CGTX) Spend Its Cash Wisely? - Dec 5th, 2025 7:46 am
Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies - Dec 3rd, 2025 5:30 am